| Literature DB >> 12657263 |
Conrad Santini1, Gregory D Berger, Wei Han, Ralph Mosley, Karen MacNaul, Joel Berger, Thomas Doebber, Margaret Wu, David E Moller, Richard L Tolman, Soumya P Sahoo.
Abstract
Beginning with the weakly active lead structure 1, a new series of hPPAR agonists was developed. In vivo glucose and triglyceride lowering activity was obtained by homologation and oxamination to 3, then conversion to substituted benzisoxazoles 4 and 5. Further manipulation afforded benzofurans 6 and 7. Compound 7 was of comparable potency as a glucose and triglyceride lowering agent in insulin resistant rodents to BRL 49653.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12657263 DOI： 10.1016/s0960-894x(03)00115-x
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823